Activated hedgehog pathway is a potential target for pharmacological intervention in biliary tract cancer

Molecular and Cellular Biochemistry

Volumn 396, Issue 1-2, 2014, Pages 257-268

  Kiesslich, Tobias ^a   Mayr, Christian ^a   Wachter, Julia ^a,b   Bach, Doris ^a   Fuereder, Julia ^a   Wagner, Andrej ^a   Alinger, Beate ^a   Pichler, Martin ^c   Di Fazio, Pietro ^d   Ocker, Matthias ^d,e   Berr, Frieder ^a   Neureiter, Daniel ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b Mistelbach Gänserndorf Regional Hospital   (Austria)

^c UNIVERSITY OF TEXAS   (United States)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

^e BAYER PHARMA AG   (Germany)

Author keywords

Biliary tract cancer; Cyclopamine; Gant 61; Hedgehog; Oncogenic signalling; Pharmacological inhibition

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPAMINE; GANT 61; GLI1 PROTEIN, HUMAN; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR; VERATRUM ALKALOID;

ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BILIARY TRACT NEOPLASMS; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; GENETICS; HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY; MUTANT MOUSE STRAIN; PATHOLOGY; PROCEDURES; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BILIARY TRACT NEOPLASMS; CELL LINE, TUMOR; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; HEDGEHOG PROTEINS; HUMANS; MICE, MUTANT STRAINS; MOLECULAR TARGETED THERAPY; PYRIDINES; PYRIMIDINES; SIGNAL TRANSDUCTION; TISSUE ARRAY ANALYSIS; TRANSCRIPTION FACTORS; VERATRUM ALKALOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907592318     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-014-2161-9     Document Type: Article

References (45)

1. Jiang J, Hui CC (2008) Hedgehog signaling in development and cancer. Dev Cell 15(6):801-812. doi: 10.1016/j.devcel.2008.11.010
2. Lum L, Beachy PA (2004) The hedgehog response network: sensors, switches, and routers. Science 304(5678):1755-1759. doi: 10.1126/science.1098020
3. Weiss GJ, Von Hoff DD (2010) Hunting the hedgehog pathway. Clin Pharmacol Ther 87(6):743-747. doi: 10.1038/clpt.2010.34
4. Kiesslich T, Neureiter D (2012) Advances in targeting the hedgehog signaling pathway in cancer therapy. Expert Opin Ther Targets 16(2):151-156. doi: 10.1517/14728222.2012.652948
5. Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Mackey HM, Lum BL, Darbonne WC, Marsters JC Jr, de Sauvage FJ, Low JA (2009) Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 361(12):1164-1172. doi: 10.1056/NEJMoa0905360
6. Patel T (2011) Cholangiocarcinoma-controversies and challenges. Nat Rev Gastroenterol Hepatol 8(4):189-200. doi: 10.1038/nrgastro.2011.20
7. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J, Investigators ABCT (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362(14):1273-1281. doi: 10.1056/NEJMoa0908721
8. Kiesslich T, Neureiter D, Wolkersdorfer GW, Plaetzer K, Berr F (2010) Advances in photodynamic therapy for the treatment of hilar biliary tract cancer. Future Oncol 6(12):1925-1936. doi: 10.2217/fon.10.147
9. Wagner A, Kiesslich T, Neureiter D, Friesenbichler P, Puespoek A, Denzer UW, Wolkersdorfer GW, Emmanuel K, Lohse AW, Berr F (2013) Photodynamic therapy for hilar bile duct cancer: clinical evidence for improved tumoricidal tissue penetration by temoporfin. Photochem Photobiol Sci 12(6):1065-1073. doi: 10.1039/c3pp25425a
10. Hopfner M, Schuppan D, Scherubl H (2008) Targeted medical therapy of biliary tract cancer: recent advances and future perspectives. World J Gastroenterol 14(46):7021-7032
11. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57-70
12. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646-674. doi: 10.1016/j.cell.2011.02.013
13. Kiesslich T, Berr F, Alinger B, Kemmerling R, Pichler M, Ocker M, Neureiter D (2012) Current status of therapeutic targeting of developmental signalling pathways in oncology. Curr Pharm Biotechnol 13(11):2184-2220
14. Kasper M, Regl G, Frischauf AM, Aberger F (2006) GLI transcription factors: mediators of oncogenic hedgehog signalling. Eur J Cancer 42(4):437-445. doi: 10.1016/j.ejca.2005.08.039
15. Varjosalo M, Taipale J (2007) Hedgehog signaling. J Cell Sci 120(Pt 1):3-6. doi: 10.1242/jcs.03309
16. Fingas CD, Bronk SF, Werneburg NW, Mott JL, Guicciardi ME, Cazanave SC, Mertens JC, Sirica AE, Gores GJ (2011) Myofibroblast-derived PDGF-BB promotes hedgehog survival signaling in cholangiocarcinoma cells. Hepatology 54(6):2076-2088. doi: 10.1002/hep.24588
17. Fingas CD, Mertens JC, Razumilava N, Sydor S, Bronk SF, Christensen JD, Rizvi SH, Canbay A, Treckmann JW, Paul A, Sirica AE, Gores GJ (2013) Polo-like kinase 2 is a mediator of hedgehog survival signaling in cholangiocarcinoma. Hepatology 58(4):1362-1374. doi: 10.1002/hep.26484
18. Jinawath A, Akiyama Y, Sripa B, Yuasa Y (2007) Dual blockade of the hedgehog and ERK1/2 pathways coordinately decreases proliferation and survival of cholangiocarcinoma cells. J Cancer Res Clin Oncol 133(4):271-278. doi: 10.1007/s00432-006-0166-9
19. Kurita S, Mott JL, Almada LL, Bronk SF, Werneburg NW, Sun SY, Roberts LR, Fernandez-Zapico ME, Gores GJ (2010) GLI3-dependent repression of DR4 mediates hedgehog antagonism of TRAIL-induced apoptosis. Oncogene 29(34):4848-4858. doi: 10.1038/onc.2010.235
20. Razumilava N, Gradilone SA, Smoot RL, Mertens JC, Bronk SF, Sirica AE, Gores GJ (2014) Non-canonical hedgehog signaling contributes to chemotaxis in cholangiocarcinoma. J Hepatol 60(3):599-605. doi: 10.1016/j.jhep.2013.11.005
21. Kiesslich T, Alinger B, Wolkersdorfer GW, Ocker M, Neureiter D, Berr F (2010) Active Wnt signalling is associated with low differentiation and high proliferation in human biliary tract cancer in vitro and in vivo and is sensitive to pharmacological inhibition. Int J Oncol 36(1):49-58
22. Wachter J, Neureiter D, Alinger B, Pichler M, Fuereder J, Oberdanner C, Di Fazio P, Ocker M, Berr F, Kiesslich T (2012) Influence of five potential anticancer drugs on wnt pathway and cell survival in human biliary tract cancer cells. Int J Biol Sci 8(1):15-29
23. de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM (1999) Biliary tract cancers. N Engl J Med 341(18):1368-1378. doi: 10.1056/NEJM199910283411807
24. Detre S, Saclani Jotti G, Dowsett M (1995) A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol 48(9):876-878
25. Kiesslich T, Neureiter D, Alinger B, Jansky GL, Berlanda J, Mkrtchyan V, Ocker M, Plaetzer K, Berr F (2010) Uptake and phototoxicity of meso-tetrahydroxyphenyl chlorine are highly variable in human biliary tract cancer cell lines and correlate with markers of differentiation and proliferation. Photochem Photobiol Sci 9(5):734-743. doi: 10.1039/b9pp00201d
26. ComboSyn Incorporated: CompuSyn for drug combinations and for general dose-effect analysis. Available via http://www.combosyn.com. Accessed 25 June 2014
27. Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58(3):621-681. doi: 10.1124/pr.58.3.10
28. Heretsch P, Tzagkaroulaki L, Giannis A (2010) Cyclopamine and hedgehog signaling: chemistry, biology, medical perspectives. Angew Chem Int Ed Engl 49(20):3418-3427. doi: 10.1002/anie.200906967
29. Lauth M, Bergstrom A, Shimokawa T, Toftgard R (2007) Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad Sci USA 104(20):8455-8460. doi: 10.1073/pnas.0609699104
30. Cai C, Rodepeter FR, Rossmann A, Teymoortash A, Lee JS, Quint K, Di Fazio P, Ocker M, Werner JA, Mandic R (2011) Nef from SIV(mac239) decreases proliferation and migration of adenoid-cystic carcinoma cells and inhibits angiogenesis. Oral Oncol 47(9):847-854. doi: 10.1016/j.oraloncology.2011.06.502
31. Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu L, Holcomb T, Stinson J, Gould SE, Coleman B, LoRusso PM, Von Hoff DD, de Sauvage FJ, Low JA (2009) Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 361(12):1173-1178. doi: 10.1056/NEJMoa0902903
32. Metcalfe C, de Sauvage FJ (2011) Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists. Cancer Res 71(15):5057-5061. doi: 10.1158/0008-5472.CAN-11-0923
33. Kim YJ, Park SB, Park JY, Park SW, Chung JB, Song SY, Bang S (2012) The sonic hedgehog pathway as a treatment target for extrahepatic biliary tract cancer. Mol Med Rep 5(1):12-16. doi: 10.3892/mmr.2011.598
34. El Khatib M, Kalnytska A, Palagani V, Kossatz U, Manns MP, Malek NP, Wilkens L, Plentz RR (2013) Inhibition of hedgehog signaling attenuates carcinogenesis in vitro and increases necrosis of cholangiocellular carcinoma. Hepatology 57(3):1035-1045. doi: 10.1002/hep.26147
35. Szkandera J, Pichler M, Absenger G, Stotz M, Weissmueller M, Samonigg H, Asslaber M, Lax S, Leitner G, Winder T, Renner W, Gerger A (2014) A functional germline variant in GLI1 implicates hedgehog signaling in clinical outcome of stage II and III colon carcinoma patients. Clin Cancer Res 20(6):1687-1697. doi: 10.1158/1078-0432.CCR-13-1517
36. Cooper MK, Porter JA, Young KE, Beachy PA (1998) Teratogen-mediated inhibition of target tissue response to Shh signaling. Science 280(5369):1603-1607
37. Berman DM, Karhadkar SS, Maitra A, Montes De Oca R, Gerstenblith MR, Briggs K, Parker AR, Shimada Y, Eshleman JR, Watkins DN, Beachy PA (2003) Widespread requirement for hedgehog ligand stimulation in growth of digestive tract tumours. Nature 425(6960):846-851. doi: 10.1038/nature01972
38. Yauch RL, Dijkgraaf GJ, Alicke B, Januario T, Ahn CP, Holcomb T, Pujara K, Stinson J, Callahan CA, Tang T, Bazan JF, Kan Z, Seshagiri S, Hann CL, Gould SE, Low JA, Rudin CM, de Sauvage FJ (2009) Smoothened mutation confers resistance to a hedgehog pathway inhibitor in medulloblastoma. Science 326(5952):572-574. doi: 10.1126/science.1179386
39. Omenetti A, Porrello A, Jung Y, Yang L, Popov Y, Choi SS, Witek RP, Alpini G, Venter J, Vandongen HM, Syn WK, Baroni GS, Benedetti A, Schuppan D, Diehl AM (2008) Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fibrosis in rodents and humans. J Clin Invest 118(10):3331-3342. doi: 10.1172/JCI35875
40. Nakanuma Y, Harada K, Ishikawa A, Zen Y, Sasaki M (2003) Anatomic and molecular pathology of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg 10(4):265-281. doi: 10.1007/s00534-002-0729-3
41. Oishi N, Wang XW (2011) Novel therapeutic strategies for targeting liver cancer stem cells. Int J Biol Sci 7(5):517-535
42. Ishimura N, Isomoto H, Bronk SF, Gores GJ (2006) Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. Am J Physiol Gastrointest Liver Physiol 290(1):G129-G136. doi: 10.1152/ajpgi.00242.2005
43. Mott JL, Kurita S, Cazanave SC, Bronk SF, Werneburg NW, Fernandez-Zapico ME (2010) Transcriptional suppression of mir-29b-1/mir-29a promoter by c-Myc, hedgehog, and NF-kappaB. J Cell Biochem 110(5):1155-1164. doi: 10.1002/jcb.22630
44. Omenetti A, Diehl AM (2011) Hedgehog signaling in cholangiocytes. Curr Opin Gastroenterol 27(3):268-275. doi: 10.1097/MOG.0b013e32834550b4
45. ClinicalTrials.gov, U.S. National Institutes of Health. Available via http://www.clinicaltrials.gov. Accessed 25 June 2014